Pluristem use the placenta as a source for stem cells, its therapy is promising for leg artery disease - Reuters (article link)

(Reuters) - Pluristem Therapeutics said early clinical trials show its placenta-derived cell therapy is safe and improves quality of life in patients with peripheral artery disease, or PAD.

- Pluristem harvests cells from the placenta after a woman gives birth, so there is no ethical issue on using embryos.
- "We have proved we can use the placenta as a source for a product that doesn't require a match between the donor and patient,"

Pluristem's clinical trials showed patients experienced improvement in bloodstream, pain and quality of life for six months following a 20-minute session of injections.